The pathogenetic role of central serotonin transporters (SERT) in obsessive-compulsive disorder (OCD) has been investigated in vivo by positron emission tomography (PET) or single-photon emission computed tomography (SPECT) studies with inconsistent results. This might reflect methodological differences but possibly also the pathophysiological heterogeneity of the disorder, i.e. the age at onset of OCD. The aim of our study was to compare SERT availability in patients with OCD to healthy controls (HC) taking into account the onset type, other factors and covariates (e.g. SERT genotype, age, depression level, gender). We studied 19 drug-naive OCD patients (36¡13 yr, eight females) with early onset (EO-OCD, n=6) or with late onset (LO-OCD, n=13), and 21 HC (38¡8 yr, nine females) with PET and the SERT-selective radiotracer [
Introduction
Obsessive-compulsive disorder (OCD) describes a clinically heterogeneous syndrome characterized by (i) intrusive obsessions which escape deliberate control, (ii) recurrent thoughts, impulses and compulsions as well as (iii) highly repetitive and ritualized behaviour or mental acts carried out in relation to these obsessions. Pathogenesis of the disorder is assumed to be linked to the central serotonergic system. This hypothesis was initially supported by the observed therapeutic efficacy of selective serotonin reuptake inhibitors (SSRIs) (Baumgarten & Grozdanovic, 1998 ; Soomro et al. 2008) ; however, pharmacological studies or measurements of the serotonin metabolite, 5-hydroxyindolacetic acid in the cerebrospinal fluid failed to prove a serotonergic involvement (Leckman et al. 1995 ; Smeraldi et al. 1996) .
Neuroimaging studies of the availability of serotonin transporters (SERT), which represent the target of SSRIs, allow direct measurement of the functional aspects of the central serotonergic system. The few studies performed to date do not reveal consistent results. When applying single-photon emission tomography (SPECT) an elevated SERT availability in the midbrain of OCD patients compared to healthy controls was reported (Pogarell et al. 2003) . Other studies found either no alteration of SERT availability (van der Wee et al. 2004) , or a reduction of SERT availability in the thalamus and hypothalamus in OCD patients (Hesse et al. 2005) , in particular in obsessive-compulsive (OC) checkers (Zitterl et al. 2007) , as well as in the midbrain/brainstem (Hasselbalch et al. 2007 ; Hesse et al. 2005) . Whereas two of those studies revealed a negative correlation between the severity of symptoms and thalamic SERT availability (Hesse et al. 2005 ; Zitterl et al. 2007) , no association of any clinical parameter with SERT availability could be demonstrated in the other reports (Hasselbalch et al. 2007 ; van der Wee et al. 2004) . In a positron emission tomography (PET) investigation with [ 11 C]McN5652 in OCD patients without comorbid depression, no major changes in SERT availability in subcortical and limbic regions were found compared to control subjects (Simpson et al. 2003) .
Several factors could explain the inconsistencies in the outcome of the studies. The studies were hampered by the fact, that the applied radiolabelled markers were not highly specific for SERT. The radiotracer [
123 I]b-CIT, which was applied in the SPECT studies, preferentially marks the dopamine transporter (Gu et al. 2001 ; Laruelle et al. 1993) , and the PET radiotracer [ 11 C]McN5652 shows low signal-to-noise ratio with high unspecific binding (Huang et al. 2002) . More recently, PET studies with the highly SERT-selective radiotracer [ 11 C]DASB revealed significantly reduced SERT availability either in the thalamus and midbrain (Reimold et al. 2007a) or in the insular cortex (Matsumoto et al. 2010) in small samples of OCD patients that were drug-naive or drug-free for at least 5 wk. However, the lack of correlation between the clinical scale of OC severity, the Yale-Brown Obsessive Compulsive Scale (YBOCS), and SERT availability (Matsumoto et al. 2010) argues against a strong association of symptoms and serotonergic dysfunction, but rather indicates secondary mechanism.
However, not only methodological differences (i.e. used radiotracer and analytical approach) might account for study differences. Not all studies were fully matched for age and gender. Previous research also indicated that there are clinical, demographic and neurobiological heterogeneities in OCD (Lochner & Stein, 2003) . OCD onset at young age differs from onset at old age genetically (more hereditary cases/stronger familial loading ; Pauls et al. 1995) . Individuals who report an early onset of OCD (EO-OCD) have higher severity and worse response to SSRIs or cognitive-behavioural therapy (Lomax et al. 2009 ; Rosario-Campos et al. 2001) . Furthermore, patients with EO-OCD had higher rates of comorbid tic disorders (Millet et al. 2004 ; Rosario-Campos et al. 2001) compared to patients with late-onset OCD (LO-OCD) while depression is more associated LO-OCD (Millet et al. 2004) .
Using SPECT imaging with [ 123 I]b-CIT, either no correlation was found between SERT availability and age at onset (Hasselbalch et al. 2007 ; Zitterl et al. 2007) , or significant differences between controls and patients were only revealed in EO-OCD (Pogarell et al. 2003) . In other [
123 I]b-CIT SPECT studies, almost all patients had EO-OCD (van der Wee et al. 2004) , or the onset age of symptoms was not considered (Hesse et al. 2005) .
The present study primarily aimed at extension of our previous SPECT studies (Hesse et al. 2005 ; Stengler-Wenzke et al. 2004 ) in order to selectively investigate SERT in untreated OCD with regard to age at onset of the disorder by applying [
11 C]DASB PET. According to our previous results we hypothesized that SERT availability is lower in OCD patients compared to healthy controls of matched age and gender. Second, we assessed the configuration of allelic variants in the promoter region of the SERT-coding gene (SERT-LPR) in order to determine the type of allele, a short (S) and/or the long (L) allele, since a functional polymorphism of the SERT-LPR might influence the SERT signal, in particular in OCD (Denys et al. 2006 ; Lin, 2007 ; Reimold et al. 2007 b) . Additionally, we investigated the STin2 VNTR polymorphism (Saiz et al. 2008) .
Methods
The study was approved by the ethics committee of the Medical Faculty of the University of Leipzig (registration number and by the competent authorities in Germany (Bundesamt fü r Strahlenschutz Z-5-22461/2 2004-035, Bundesinstitut fü r Arzneimittel and Medizinprodukte 61-3900-4022972). The study was performed in accordance with the ICH Guideline for Good Clinical Practice (June Helsinki.
Participants
Nineteen patients with OCD (age 36¡13 yr, eight females) and without psychiatric comorbidity, diagnosed by two experienced psychiatrists according to DSM-IV and ICD-10 criteria (F42.0-2), participated in this study. All patients had never received psychopharmacotherapy or other drugs affecting brain neurotransmitter, and patients with current drug or alcohol abuse were excluded. OCD severity was assessed with the YBOCS (Goodman et al. 1986a, b) . The level of depressive symptoms was rated using the Beck Depression Inventory (BDI ; Beck et al. 1961) . We defined 'age at onset ' as the age in which patients remembered the beginning of clinically significant distress or impairment associated with obsessions and/or compulsions. Patients with OCD were divided into two groups according to age at onset : i.e. f17 yr (early-onset type, EO-OCD ; n=6 ; age 35¡10 yr, duration of OCD 18¡11 yr ; two females), or o18 yr (lateonset type, LO-OCD ; n=13 ; age 36¡14 yr, duration of OCD 8¡4 yr, six females) ( Table 1 ). This threshold was indicated by most of the studies showing differences in clinical and therapeutic features as well as different familial loading (Fontenelle et al. 2003 ;  Berman et al. 2005) and urine screening by spot checks. All patients and healthy control subjects gave their written informed consent.
PET and imaging data analysis
]DASB was synthesized according to Wilson et al. (2000) . Patients underwent dynamic PET for 90 min after intravenous bolus injection (90 s) of (mean+S.D.) 425¡145 MBq [ 11 C]DASB using the ECAT EXACT HR+ scanner [Siemens, Germany ; intrinsic resolution at the centre : 4.3 mm, axial resolution : 5-6 mm field of view 15.5 cm, 3-4 mm full-width at half maximum (FWHM)] in two-dimension acquisition mode. Emission scan duration was 90 min acquiring 23 frames (4r0.25, 4r1, 5r2, 5r5, 5r10 min). We used a 10-min-transmission scan (from three 68 Ga/ 68 Ge sources), which was performed prior the emission scan, for attenuation correction and filtered backprojection (128r128, voxel size 2.6r2.6r2.4 mm) with a Hann filter (cut-off 4.9 mm) for image reconstruction. After smoothing of reconstructed images (10 mm isotropic Gaussian filter), parametric images of SERT distribution volume ratios (DVRs ; Innis et al. 2007) were generated from the PET data by the multilinear reference tissue model with two parameters (MRTM2) with the cerebellar grey matter as the reference tissue (Ichise et al. 2003 ; Kim et al. 2006) . Regional analyses of DVR values were performed after coregistration of DVR images with 3D magnetic resonance imaging (MRI) data (T1-weighted Magnetom, Symphonie, 1.5 T, Siemens, Germany ; 3D MPRAGE, time of repetition 11.4 ms, time of echo 4.4 ms, 128 slices, matrix 256r256, voxel size 0.9r0.9r1.5 mm) using the MultiModality software (Hermes Medical Solutions, Sweden) for re-alignment and stereotactical normalization (according to the anterior commissure-posterior commissure line), and delineating the volumes of interest (VOI ; striatum : the head of the caudate and the putamen, the thalami, the hypothalamus, midbrain, brainstem raphe nuclei, amygdala, hippocampus, and cortical areas) at adjacent planes. The reference tissue clearance rate constant k 2 ' for MRTM2 was computed from VOI time-activity curves. VOIs were directly drawn into the PET images in the raphe nuclei as transporter-rich regions and into the cerebellum. There were no differences in the mean values between patient (0.0484¡0.0074/min, n=19) and healthy control (0.0486¡0.0094/min, n=21) groups (p=0.96).
A voxelwise statistical analysis was performed using SPM2 (Statistical Parametric Mapping, Wellcome Department of Cognitive Neurology, UK) implemented in Matlab 7.3.0 (The MathWorks Inc., USA). Mean images (70-90 min p.i.) were spatially normalized on the SPM2 integrated PET template and smoothed with 12 mm FWHM on a Gaussian filter. Group comparisons (unpaired t test, healthy controls vs. OCD patients, or EO-OCD/LO-OCD patients) were considered significant for p<0.001 (T>3.5), unadjusted for multiple comparisons, and a minimum of 30 voxels/cluster. Genotyping DNA-isolation : Genomic DNA was obtained from 2 ml peripheral blood, with EDTA as anticoagulant and the peqGold Blood DNA Mini kit from peqLab (Erlangen, Germany) according to the manufacturer's instructions. The SERT-LPR serotonin gene polymorphism study was performed by amplification with polymerase chain reaction (PCR) and a standardized procedure with primers synthesized by Invitrogen (UK), and additionally, the primers described by Heils et al. (1996) . Results were confirmed by re-genotyping. The VNTR gene polymorphism was examined by amplification with primers as described by Ogilvie et al. (1996) with modifications. Primers were synthesized by Invitrogen (Germany) and all PCRs were performed standardized, in duplicate, and repeated at least once, twice or three times. The PCR products were visualized by gel electrophoresis in agarose gels (peq Gold Universal agarose, peqLab, Germany) with 1rTAE solution and stained with ethidium bromide, Ultraviolet light was used for visualization of the fluorescent stain. For size definition the 100-bp ladder (for SERT-LPR) from Amersham Biosciences Europe, Germany, or the peq Gold 50-bp DNA ladder (for VNTR) from peqLab (Germany), were used.
Statistical analysis
The data were tested for normal distribution using the Shapiro-Wilks test and the Levene test for homogeneity of variance. When variables were not normally distributed, the Wilcoxon-Mann-Whitney U test was applied as a non-parametric test. After thorough review and tests excluding asymmetries between corresponding left and right brain regions, VOIs were averaged in contralateral, corresponding VOIs from each hemisphere in order to reduce the number of dependent variables within the statistical models resulting in 18 VOIs (pooled or unique), which were used in further analyses. Multivariate analyses of covariance were performed to compare the groups of healthy controls and OCD patients regarding differences between the measured DVRs within all those brain VOIs. Due to the rather small sample sizes and reduced availability/suitability of various potentially prognostic covariates a sequential strategy of analyses was applied. First, a model was applied using all cases with factor-variable group membership (patients vs. healthy control cohort) and SERT-LPR type as well as their interaction and including all epidemiological characteristics and BDI as covariates (complete dataset for n=34). In a second step, only OCD patients were included using onset type of disease and both genotyping characteristics (SERT-LPR and VNTR) as factors including the SERT-LPRrVNTR interaction and sex, age, onset age, body mass index (BMI), smoking habits, BDI, and YBOCS as covariates. Partial correlation coefficients were further calculated to reveal associations between DVRs, epidemiological (age, type of onset, BMI, and smoking habits) and clinical data. An alpha-adjustment with respect to multiple testing was not performed due to the primarily exploratory character of the study.
Results
SPM analysis revealed significant group differences between OCD patients and healthy controls in distinct brain regions as indicated in Table 2 and Fig. 1 . There were clusters with lower activities in either LO-OCD or EO-OCD groups compared to healthy controls as well as clusters with higher activities in EO-OCD compared to controls. Consecutive VOI analysis revealed significantly lower DVRs in the LO-OCD group compared to controls, and the EO-OCD group consistently in the nucleus accumbens, the amygdala/ hippocampus, striatal regions, and the occipital cortex (Fig. 2) . However, DVRs of EO-OCD patients did not Considering all factors, covariates and the most interactions analysed within the multivariate analyses of covariance no significant differences could be found using the MANCOVA multivariate tests between OCD patients and healthy controls. For distinct VOIs, however, factors and covariates showed significant or borderline-significant effects in the univariate approach (as indicated in Tables 3 and 4 ). For instance, significant differences between OCD patients and healthy controls were found in the anterior cingulate cortex (ACC) (p=0.02) where BDI and agerBDI showed a borderline-significant effect on DVR, too. The DVRs of EO-OCD and LO-OCD groups differed significantly in the nucleus accumbens (p=0.04), amygdala (p=0.02), and putamen region (p=0.01, Table 4 , Fig. 2) .
No interaction between the presence of the disorder and SERT-LPR was observed (Table 3) . When analysing both SERT-LPR and VNTR within the patients ' subset only (Table 4) Fig. 2 . Serotonin transporter distribution volume ratios (DVR) in patients with early-onset obsessive-compulsive disorder (EO-OCD, n=6), late-onset OCD (LO-OCD, n=19) and healthy comparison subjects (HC, n=21). Significant between-group differences are set up at * p<0.05, and ** p<0.01 for LO-OCD vs. HC, and # p<0.05 for LO-OCD vs. EO-OCD (t test, non-adjusted for multiplicity ; for corrected p values see Tables 3 and 4 ). (For abbreviations on x axis see Table 3 note.) the putamen, and the hypothalamus) were presented with significant interactions between the two SERT gene polymorphisms. In summarizing these findings, more differences were identified between the cohorts of different onset types than between the patient and healthy control groups studied. Neither epidemiological variables nor clinical data differed between EO-OCD and LO-OCD groups. However, YBOCS (24¡6 vs. 19¡2, p=0.04) showed a significant imbalance between both groups whereas BDI did not (14¡9 vs. 13¡4, p=0.50). However, partial correlation revealed, no significant association between YBOCS or BDI and DVRs in any brain region in all patients or in the EO-OCD/LO-OCD groups separately (results not presented in detail).
There was an overall trend towards higher DVRs in SS carriers in all investigated regions reaching significance (vs. LL carriers) in the midbrain (Fig. 3) .
Discussion
This study demonstrates that in-vivo SERT availability is reduced in drug-naive OCD patients with older age at disease onset (LO-OCD) compared to age-and gender-adjusted healthy controls. This reduction was seen in distinct brain regions particularly in limbic areas, such as the ventral striatum, the amygdala, and the hypothalamus. No abnormalities were found in EO-OCD patients. This is, to our knowledge, the first report on specific age at onset-related changes of SERT in OCD measured with a SERT-selective PET radiotracer, which considers potential covariates such as age (Buchert et al. 2006 ; Hesse et al. 2003 ; Reimold et al. 2007a) , gender (Jovanovic et al. 2008) , smoking (Staley et al. 2001) , depression levels (Eggers et al. 2003) and BMI (Erritzoe et al. 2010) . The fact that SERT availability is not altered in EO-OCD patients corroborates previous SPECT findings of normal (van der Wee et al. 2004), or even higher SERT availability in OCD patients compared to healthy controls (Pogarell et al. 2003) . These results emphasize that EO-OCD differs from LO-OCD not only epidemiologically, but rather represents a phenomenologically and aetiologically distinct subtype of OCD, bearing a genetic relationship to tic and other OC spectrum disorders (Lochner & Stein, 2003 ; Millet et al. 2004 ; Rosario-Campos et al. 2001) . In addition, the unaltered SERT availability in EO-OCD patients might explain their worse response to SSRIs (Rosario-Campos et al. 2001) .
For whole-group comparison vs. healthy subjects, a reduction of SERT availability only in the paralimbic ACC, a region involved in reappraisal and suppression of negative emotions and inhibition control, was found in our study. The predominant limbic reduction of SERT availability is a new finding and corresponds with data of a recent [ 11 C]DASB PET study in depression-free, drug-free OCD patients which found diminished insular SERT availability (Matsumoto et al. 2010) . The reduced number of limbic SERT-binding sites might be associated with chronically higher serotonergic input in those regions closely related to anxiety-like behaviours. This is supported by the fact that individuals with OCD exhibited significant amygdala activation in addition to activation in frontal, anterior temporal, ACC, insular cortex, and caudate nucleus after symptom provocation (Breiter & Rauch, 1996) . Such a model describes an overactivity in parts of a cortico-striato-thalamic-cortical (CSTC) loop connecting the orbito-frontal cortex, (OFC), the ACC, and the caudate (Saxena et al. 1998 ) relevant for the cognitive features seen in OCD. The changes in putaminal SERT might indicate failures to subserve cognitive function with implement sensorimotor coordination. Corroborating the findings of previous SPECT studies, we also demonstrated a reduction of SERT availability in the thalamus, which may be due to an increased dopaminergic drive from striatal projections. Together with a dysfunctional sensory gating in the CSTC circuit it explain deficits in executing appropriate adaptive behaviours and results in obsessive thoughts and obsessions. Here, we found no association between thalamic SERT availability and OC symptoms in accord with our SPECT study (Hesse et al. 2005) . This could be attributed to the previous use of the radiotracer [
123 I]b-CIT, which superposes or adds serotonergic and dopaminergic imbalances, or point to the fact that the thalamic activity represents more a state (or a mechanism secondary to frontallimbic activation) whereas SERT availability is a trait marker. In keeping with this, Matsumoto et al. (2010) also failed to find a correlation of clinical severity (YBOCS) and SERT availability.
In accordance with a serotonergic-dopaminergic imbalance, the reduced SERT availability fits well with a hypothesis of a down-regulation of dopamine D 1 receptors in the caudate nucleus and putamen as measured with [
11 C]SCH23390 and PET, and D 2 receptor down-regulation (Olver et al. 2009 ; Perani et al. 2008) , which express the higher nigrostriatal dopaminergic drive modulating the CTSC loop via both the D 1 and D 2 receptors. In addition, an increased 5-HT 2A receptor binding measured with [
18 F]altanserin and PET in caudate nuclei was found, which again did not correlate with the severity of OCD. This finding suggests compensatory up-regulation due to serotonin lack or higher serotonin turnover in the feedback loop between the thalamus, OFC, and the caudate nuclei (Adams et al. 2005) . Accordingly, the serotonergic dysfunction involves frontal and associative temporal and parietal regions as demonstrated by a reduction of [
11 C]MDL 100,907 binding to 5-HT 2A receptor (Perani et al. 2008) . We found the greatest difference of SERT availability in the dorsal parts of the striatum, not in the head of the caudate. This is also in line with Table 3 note.)
findings of a recent meta-analysis (Rotge et al. 2010) , which indicated structural alterations in parieto-frontal regions and putamen, but showed no evidence of alterations in the hippocampus and caudate. Whether abnormalities of the dopaminergic system in particular rather than changes of the serotonergic system are involved in the pathogenesis of EO-OCD needs to be further investigated. Taking all the relevant SPECT and PET data together, failure to identify distinct serotonergic abnormalities may be due to differences in applied methods including data analysis (in our study SPM and VOI analyses) and different subtypes. However, with regard to the widely distributed serotonergic innervations it is of further interest whether specific regional alterations exist and how SERT contributes to the significance of the regional variation. An altered serotonergic tone for maintaining homeostasis might help to promote symptom generation. Causal mechanisms (correlating with symptom severity) or compensatory (coping) mechanisms can coexist. Variation of SERT outcome measures might, thus, reflect a pattern of complex regulatory changes of distinct serotonergic pathways related to the individual phenotype. This needs more investigations in a larger sample with distinct symptom dimensions not at least due to the heterogeneous picture of SERT abnormalities.
Because the initial intention of the study was to compare OCD patients with healthy age-and gendermatched controls and this was not a stratified trial with regard to age of onset, we were, unfortunately, not able to recruit a balanced number of patients for each group within the time window of the approval of this study. Our patients did not have comorbid depression and clinical characteristics ; YBOCS and BDI were not sufficiently homogeneous to be considered consistently as cofactors. This is, however, with regard to the above mentioned trait-state issue a major concern since in our study YBOCS differed between EO-OCD and LO-OCD in non-parametric tests, and multivariate analyses revealed significant interaction of YBOCS with DVR in the ACC and the putamen. Thus, to draw a definite conclusion on the state of clinical disease severity in relation to regional DVRs, we need a prospective case-by-case replication evaluation with homogenized inclusion criteria, e.g. a cutoff YBOCS value. It is of further interest, too, whether abnormally low SERT availability in LO-OCD might explain the relatively high comorbidity rates of depression in LO-OCD compared to that in EO-OCD.
Genetic determination, in particular SERT-LPR, might also influence in-vivo SERT availability (Reimold et al. 2007b) . This is also supported by the data of our study, and hence, SERT-LPR can be regarded as a covariate so that study subjects should further be matched for genotype. However, the real impact of SERT-LPR (and VNTR, Saiz et al. 2008 ) is an open issue (Parsey et al. 2006 ) and needs to be further investigated. Association studies revealed hints for a relationship between SERT-LPR and the occurrence of OCD. Therefore, OCD was associated with the SS homozygous genotype (Denys et al. 2006 ; Hasler et al. 2006 ; Lin, 2007) . Although we found a tendency towards higher SERT availability in SS carriers there were no significant effects of SERT-LPR or/and VNTR on in-vivo SERT availability. Whether higher SERT levels in SS carriers predispose to disorder vulnerability needs further studies in larger cohort trials.
Altogether, our data support a dysfunction of the serotonin system as a trait of OCD with late onset, in particular in limbic areas. This complements recent morphometric and functional MRI studies suggesting a dorsal prefrontal-striatal model of affected brain regions in OCD including dorsal striatum and lateral prefrontal cortex, and of the ventral striatum (the nucleus accumbens) with the region of the midbrain ventral tegmental area (Harrison et al. 2009 ; Radua & Mataix-Cols, 2009 ). Herein, functional alterations in cortical regions commonly linked with OCD such as the OFC, or in the thalamus may reflect secondary changes. Regional SERT specificity in terms of local adaptation for network stability might be most critical for serotonin homeostasis but this assumption has also to be replicated with larger study samples.
